Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista NDA

TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ( " Intellipharmaceutics " or the " Company " ), a pharmaceutical company specializing in the research, development and manufacture of novel and...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news